Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128403 | 0.90 | DPP8 (0.40) | NPC1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL14174877 | 0.86 | NPC1 (0.43) | NPC1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL24491469 | 0.84 | CHRNB2 (0.41) | NPC1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL18330354 | 0.83 | GNAI3 (0.51) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL14174867 | 0.81 | NPC1 (0.69) | NPC1ALDH1A1 | |
| SCHEMBL8430100 | 0.81 | ITGB3 (0.43) | NPC1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL12384628 | 0.81 | NPC1 (0.44) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL11981636 | 0.80 | NPC1 (0.47) | NPC1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL19502819 | 0.80 | GNAI3 (0.58) | NPC1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL27429180 | 0.80 | GNAI3 (0.60) | NPC1GNAI3GNAO1GNAI1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102419-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | Epizyme, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NPC1 1362/4885GNAI3 3226/4885GNAO1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.